Heart Disease and Diabetes: New Data From ACC/WCC 2023

Jorge Plutzky, MD


March 24, 2023

Dr Jorge Plutzky, of the Brigham and Women's Hospital, Boston, Massachusetts, highlights important studies on diabetes and heart disease presented at the American College of Cardiology (ACC) Scientific Session/World Congress of Cardiology (WCC) 2023.

Dr Plutzky first reports on the late-breaking results of the COORDINATE trial, which examined whether prescription use of three guideline-directed therapies would increase if a medical intervention team were available to patients. The study showed that patients in the intervention arm were more likely to be prescribed all three therapy classes.

Next, Dr Plutzky discusses a trial that used National Health and Nutrition Examination Survey data to assess cardiovascular risk among US adults aged 18-44. Risk factors for heart disease have increased among all, but ethnic disparities were also prevalent.

He then turns to a study looking at whether medication adherence rates would increase for common heart and diabetes medications if patient costs were eliminated. Surprisingly, adherence in the intervention group did not differ significantly from that in the control group.

Finally, Dr Plutzky highlights a study examining whether dapagliflozin would reduce the rate of either initiation of new therapy or intensification of existing therapy in patients with heart failure and diabetes. Dapagliflozin reduced the new-use insulin rate and did not intensify existing dosing.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.